Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

摘要: PURPOSE: To evaluate whether the addition of gemcitabine (G) to vinorelbine (V) improves survival and quality life (QoL) among elderly patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients NSCLC aged ≥ 70 years disease were randomly allocated receive V 30 mg/m2 on days 1 8 every 3 weeks or G 1,200 + weeks. The estimated sample size was 120 per arm, but an interim analysis planned based first 60 arm. RESULTS: In May 1999, data analyzed eligible (V group = 60; 60) who had been randomized from June 1997 February 1999. Forty-nine stage IIIB disease, 71 IV. At a median potential follow-up 14 months (range, 22 months), 93 died (G 41; 52). group, time 29 projected 1-year 30%; these values w...